Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Wright W. Nichols"'
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 21, Iss 5, Pp 569-573 (2017)
Externí odkaz:
https://doaj.org/article/98455387054640ef9d3c7220c8186955
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:871-892
As one of a series of thematically linked reviews of the primary pharmacology of the β-lactam/β-lactamase inhibitor combination, ceftazidime/avibactam, this article reviews the microbiological findings in drug-exposed patients. Earlier articles in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::731987dc006077bd7f5da7783ddf6edf
https://doi.org/10.1093/jac/dkad049
https://doi.org/10.1093/jac/dkad049
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:569-585
This article reviews resistance to ceftazidime/avibactam as an aspect of its primary pharmacology, linked thematically with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3200b69eec0edfe1281bddc2534c8f0a
https://doi.org/10.1093/jac/dkac449
https://doi.org/10.1093/jac/dkac449
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:2341-2352
This review describes the translational in vivo and non-clinical pharmacokinetics/pharmacodynamics (PK/PD) research that supported clinical trialling and subsequently licensing approval of ceftazidime/avibactam, a new β-lactam/β-lactamase inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1693b1e1c53208944a1d033065a50ce9
https://doi.org/10.1093/jac/dkac172
https://doi.org/10.1093/jac/dkac172
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Ceftazidime–avibactam is a novel β-lactam/β-lactamase inhibitor combination recently approved in Europe and the USA for the treatment of adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), among other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cfd6d0af91ba2501e02dcfc86a13444
http://europepmc.org/articles/PMC7223046
http://europepmc.org/articles/PMC7223046
Autor:
Johanna, Berkhout, Maria J, Melchers, Anita C, van Mil, Claudia M, Lagarde, Wright W, Nichols, Johan W, Mouton
Publikováno v:
Journal of chemotherapy (Florence, Italy). 33(6)
The post-antibiotic effect (PAE) of ceftazidime-avibactam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8117b19b967cd5d067d8a0820e8eabbe
https://pubmed.ncbi.nlm.nih.gov/33682636
https://pubmed.ncbi.nlm.nih.gov/33682636
Autor:
Sherwin K. B. Sy, Marie-Eve Beaudoin, Wright W. Nichols, Virna J A Schuck, Huiming Xia, Hartmut Derendorf, Luning Zhuang
Publikováno v:
Journal of Antimicrobial Chemotherapy. 73:1295-1304
Objectives To characterize quantitatively the effect of avibactam in potentiating ceftazidime against MDR Pseudomonas aeruginosa by developing a mathematical model to describe the bacterial response to constant concentration time-kill information and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc17797ac2e06ea596096b3a613254e2
https://doi.org/10.1093/jac/dkx537
https://doi.org/10.1093/jac/dkx537
Autor:
Kevin M. Krause, Wright W. Nichols, Peter J. Laud, Eric Gangl, Petar Pop-Damkov, Taryn Sleger, Andrew M Slee
Publikováno v:
Journal of Chemotherapy. 30:95-100
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d38c3bec2cda44dd6091c8698afcb3c7
https://doi.org/10.1080/1120009x.2017.1405609
https://doi.org/10.1080/1120009x.2017.1405609
Publikováno v:
International Journal of Antimicrobial Agents. 49:437-442
Avibactam is a novel non-β-lactam β-lactamase inhibitor being developed in combination with ceftazidime, ceftaroline and aztreonam for the treatment of infections caused by Gram-negative bacteria. Avibactam protects the antibacterial activity of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a22b6b5d56cdaa432c512c96c8f7cadd
https://doi.org/10.1016/j.ijantimicag.2016.12.011
https://doi.org/10.1016/j.ijantimicag.2016.12.011
Autor:
Paul Newell, Jianguo Li, Timothy J. Carrothers, David Melnick, Todd Riccobene, Gregory G. Stone, Wright W. Nichols, Shampa Das, Ian A. Critchley
Publikováno v:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Avibactam is a non-β-lactam β-lactamase inhibitor that has been approved in combination with ceftazidime for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia, including ventilat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4630cd651bb20617d4e54f473b0d17b2
